688488.SH
Jiangsu Aidea Pharmaceutical Group Co., Ltd.
SSE · Healthcare · Biotechnology · CN
CNY 12.61
+2.11%Oct 29, 2026, 09:30 UTC
Jiangsu Aidea Pharmaceutical plans to repurchase its shares for RMB 10 million to RMB 20 million through centralized bidding, at no more than RMB 22.39 per share, for an employee shareholding plan or equity incentives.
Source:Oct 16, 2026, 07:55 UTC
Aidi Pharmaceutical's board approved the planned dissolution of its wholly owned subsidiary Nanjing Ansailai Pharmaceutical Technology Co., Ltd. to consolidate resources and reduce management costs.
Source:Sep 17, 2026, 10:55 UTC
Aidea Pharmaceutical's board approved a 2026 plan to issue A-shares to specific investors, raising no more than RMB 945 million for the global clinical development of novel HIV integrase inhibitors, an annual production project of 500 million anti-HIV solid dosage form drugs, and supplemental working capital.
Source:Aug 28, 2026, 09:20 UTC
Aide Pharmaceutical announced its first-half 2026 results with revenue of 366 million yuan, up 0.93% year-on-year, and net profit attributable to shareholders of 22.93 million yuan, up 149.53% year-on-year.
Source:Aug 18, 2026, 08:04 UTC
Fu Hexiang, a person acting in concert with the actual controller of Aidea Pharmaceutical, pledged 4.5 million shares of the company to Shenzhen Shendan Credit Enhancement Financing Guarantee Co., Ltd. on August 17, 2026, for personal funding needs.
Source: